San Diego, CA -- (SBWire) -- 03/08/2023 --An investigation was announced over potential breaches of fiduciary duties by certain officers and directors at Design Therapeutics, Inc.
Investors who purchased shares of Design Therapeutics, Inc. (NASDAQ: DSGN) have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.
The investigation by a law firm concerns whether certain Design Therapeutics, Inc. (directors breached their fiduciary duties and caused damage to the company and its shareholders.
Carlsbad, CA based Design Therapeutics, Inc. a preclinical-stage biopharmaceutical company, engages in the development of therapies for the treatment of genetic diseases caused by nucleotide repeat expansions. On or around March 24, 2021, Design Therapeutics, Inc. conducted its initial public offering ("IPO"), selling 12 million shares of stock priced at $20.00 per share.
Then, on December 7, 2022, Design Therapeutics, Inc. reported initial data from a Phase 1 trial of DT-216 in patients with Friedreich ataxia. Among other results, Design said 16 patients on DT-216 and eight on placebo reported at least one treatment-emergent adverse event.
Shares of Design Therapeutics, Inc. (NASDAQ: DSGN) declined from $24.85 per share on August 09, 2022, to as low as $6.46 per share on March 02, 2023.
Those who purchased shares of Design Therapeutics, Inc. (NASDAQ: DSGN) have certain options and should contact the Shareholders Foundation.
Contact:
Shareholders Foundation, Inc.
Michael Daniels
3111 Camino Del Rio North - Suite 423
92108 San Diego
Phone: +1-(858)-779-1554
Fax: +1-(858)-605-5739
mail@shareholdersfoundation.com
About The Shareholders Foundation
The Shareholders Foundation, Inc. is a professional portfolio monitoring and settlement claim filing service, , which does research related to shareholder issues and informs investors of securities class actions, settlements, judgments, and other legal related news to the stock/financial market. Shareholders Foundation, Inc. is in contact with a large number of shareholders and offers help, support, and assistance for every shareholder. The Shareholders Foundation, Inc. is not a law firm. Referenced cases, investigation, and/or settlements are not filed/reached and/or related to Shareholders Foundation. The information is provided as a public service. It is not intended as legal advice and should not be relied upon.
Design Therapeutics, Inc. (NASDAQ:DSGN) Investor Alert: Investigation Concerning Possible Wrongdoing
An investigation on behalf of investors in Design Therapeutics, Inc. (NASDAQ:DSGN) shares over potential wrongdoing at Design Therapeutics, Inc. was announced.